medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2017, Number 5

<< Back Next >>

Rev Invest Clin 2017; 69 (5)

Prevalence of Human Papillomavirus in Women from the State of Michoacan, Mexico, Showed High Frequency of Unusual Virus Genotypes

Jácome-Galarza I, Ito-Nakashimada MA, Figueroa-Aguilar G, García-Latorre E, Salazar IMA; López-Orduña E, Camacho AD, Valdez-Alarcón JJ, Hernández JM, León-Avila G

Language: English
References: 37
Page: 262-269
PDF size: 179.30 Kb.


ABSTRACT

Background: Human papillomaviruses (HPVs), the leading cause of cervical cancer, are distributed worldwide, with high prevalence in developing countries. Objective: The objective of the study is to know the prevalence and genotypes of HPV in women from the state of Michoacán and the Women’s Hospital in Morelia, Michoacán. Materials and Methods: Cervical smear samples (159,288) were subjected to HPV detection by hybrid capture 2. A subsample of 484 patients from the Women’s Hospital was studied by Papanicolaou test and linear array HPV genotyping, and when positive, patients were also examined by colposcopy and histopathology. Results: The overall prevalence for HPV in Michoacán State was 7.74%; 7.11% in 2009, 6.46% in 2010, 9.58% in 2011, and 8.43% in 2012. The highest prevalence was found in the age groups ‹ 25 and 25-34 years. The prevalence at the Women’s Hospital was 8.51%. Cytological examination revealed normal cytology in 64.44% of samples, 26.66 % with low-grade and 8.88 % with high-grade squamous intraepithelial lesion (HSIL). However, by colposcopy, normal tissue appearance was found only in 26.66%; 51% were reclassified as low-grade squamous intraepithelial lesion, 17.77% as HSIL, and in 4.4% atrophy was observed. The most prevalent genotype in single infections was HPV59, followed by HPV51 and HPV45. Double infections occurred with the following genotypes: 52-53, 51-59, 61-67, 66-11, 16-62, 53-62, 59-CP6108, 45-66, and 45-51. Triple infections were identified as: 6-31-39, 51-59-62, 51-62-81, 54-55-59, 16-58-71, and 16-59-62. Conclusions: The prevalent genotype found among women from Michoacán, HPV59, was different to the rest of the country. The high prevalence of HPV59 could be due to cases imported to Michoacán by agricultural workers migrating to the USA or may be associated to ethnicity differences. Implications of this finding for immunization programs should be explored.


REFERENCES

  1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-9.

  2. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382:889-99.

  3. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes. 2010;40:1-13.

  4. Fu L, Van Doorslaer K, Chen Z, Ristriani T, Masson M, Travé G, et al. Degradation of p53 by human Alphapapillomavirus E6 proteins shows a stronger correlation with phylogeny than oncogenicity. PLoS One. 2010;5. pii: e12816.

  5. Roman A. The human papillomavirus E7 protein shines a spotlight on the pRB family member, p130. Cell Cycle. 2006;5:567-8.

  6. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401:70-9.

  7. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30 Suppl 5:F55-70.

  8. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.

  9. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis. 2007;7:453-9.

  10. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: Metaanalysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202:1789-99.

  11. Flores YN, Bishai DM, Shah KV, Lazcano-Ponce E, Lörincz A, Hernández M, et al. Risk factors for cervical cancer among HPV positive women in Mexico. Salud Publica Mex. 2008;50:49-58.

  12. Palacio-Mejía LS, Rangel-Gómez G, Hernández-Avila M, Lazcano- Ponce E. Cervical cancer, a disease of poverty: Mortality differences between urban and rural areas in Mexico. Salud Publica Mex. 2003;45 Suppl 3:S315-25.

  13. Lazcano-Ponce E, Lörincz AT, Salmerón J, Fernández I, Cruz A, Hernández P, et al. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program. Cancer Causes Control. 2010;21:1693-700.

  14. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 3.0. Available from: http://www.OpenEpi.com. [Last updated on 2013 04 Apr 06].

  15. Weiss N.S. Clinical epidemiology. In: Rothman KJ, Grennland S, Lash TL, editors. Modern Epidemiology. 3rd ed. Ch. 23. Philadelphia, PA, USA: Lippincot Williams and Wilkins; 2008. p. 641-51.

  16. López-Revilla R, Martínez-Contreras LA, Sánchez-Garza M. Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma. Infect Agent Cancer. 2008;3:3.

  17. Granados-García V, Flores YN, Pérez R, Rudolph SE, Lazcano- Ponce E, Salmerón J. Cost of the cervical cancer screening program at the mexican social security institute. Salud Publica Mex. 2014;56:502-10.

  18. Lazcano-Ponce E, Palacio-Mejia LS, Allen-Leigh B, Yunes-Diaz E, Alonso P, Schiavon R, et al. Decreasing cervical cancer mortality in Mexico: Effect of Papanicolaou coverage, birthrate, and the importance of diagnostic validity of cytology. Cancer Epidemiol Biomarkers Prev. 2008;17:2808-17.

  19. Beal CM, Salmerón J, Flores YN, Torres L, Granados-García V, Dugan E, et al. Cost analysis of different cervical cancer screening strategies in Mexico. Salud Publica Mex. 2014;56:429-501.

  20. Flores YN, Bishai DM, Lorincz A, Shah KV, Lazcano-Ponce E, Hernández M, et al. HPV testing for cervical cancer screening appears more cost-effective than Papanicolaou cytology in Mexico. Cancer Causes Control. 2011;22:261-72.

  21. Salcedo M, Pina-Sanchez P, Vallejo-Ruiz V, Monroy-Garcia A, Aguilar-Lemarroy A, Cortes-Gutierrez EI, et al. Human papillomavirus genotypes among females in Mexico: A study from the Mexican institute for social security. Asian Pac J Cancer Prev. 2014;15:10061-6.

  22. Aguilar-Lemarroy A, Vallejo-Ruiz V, Cortés-Gutiérrez EI, Salgado- Bernabé ME, Ramos-González NP, Ortega-Cervantes L, et al. Human papillomavirus infections in Mexican women with normal cytology, precancerous lesions, and cervical cancer: Type-specific prevalence and HPV coinfections. J Med Virol. 2015;87:871-84.

  23. Castle PE, Solomon D, Wheeler CM, Gravitt PE, SWacholder PE, Schiffman M. Human papillomavirus genotype. Specificity of hybrid capture 2. J Clin Microbiol. 2008;6:2595-604.

  24. DelaRosa-Martínez R, Sánchez-Garza M, López-Revilla R. HPV genotype distribution and anomalous association of HPV33 to cervical neoplastic lesions in San Luis Potosí, Mexico. Infect Agent Cancer. 2016;11:16.

  25. Flores-Miramontes MG, Torres-Reyes LA, Alvarado-Ruíz L, Romero-Martínez SA, Ramírez-Rodríguez V, Balderas-Peña LM, et al. Human papillomavirus genotyping by linear array and next-generation sequencing in cervical samples from Western Mexico. Virol J. 2015;12:161.

  26. González-López S, Martínez-Silva MG, Hernández-Hernández DM, Aguilar-Lemarroy A, Jave-Suárez LF. Frequency of cervical epithelial lesions reported in the Regional Laboratory of Exfoliative Cytology in Jalisco. Rev Med Inst Mex Seguro Soc. 2015;53 Suppl 2:S132-9.

  27. Das Ghosh D, Mukhopadhyay I, Bhattacharya A, Roy Chowdhury R, Mandal NR, Roy S, et al. Impact of genetic variations and transcriptional alterations of HLA class I genes on cervical cancer pathogenesis. Int J Cancer. 2017;140:2498-508.

  28. Chen D, Gaborieau V, Zhao Y, Chabrier A, Wang H, Waterboer T, et al. A systematic investigation of the contribution of genetic variation within the MHC region to HPV seropositivity. Hum Mol Genet. 2015;24:2681-8.

  29. Hernández-Hernández DM, Cerda-Flores RM, Juárez-Cedillo T, Granados-Arriola J, Vargas-Alarcón G, Apresa-García T, et al. Human leukocyte antigens I and II haplotypes associated with human papillomavirus 16-positive invasive cervical cancer in Mexican women. Int J Gynecol Cancer. 2009;19:1099-106.

  30. Fernández-Tilapa G, Illades-Aguiar B, Martínez-Carrillo DN, Alarcón- Romero LC, Vences-Velázquez A, Terán-Porcayo MA, et al. Prevalence of human papillomavirus types among Mexican women with intraepithelial lesions and cervical cancer: Detection with MY09/MY011 and GP5+/GP6+ primer systems. Am J Infect Dis. 2007;3:62-7.

  31. Lazcano-Ponce E, Pérez G, Cruz-Valdez A, Zamilpa L, Aranda-Flores C, Hernández-Nevarez P, et al. Impact of a quadrivalent HPV6/11/16/18 vaccine in Mexican women: Public health implications for the region. Arch Med Res. 2009;40:514-24.

  32. Skinner SR, Wheeler CM, Romanowski B, Castellsagué X, Lazcano-Ponce E, Del Rosario-Raymundo MR, et al. Progression of HPV infection to detec` cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. Int J Cancer. 2016;138:2428-38.

  33. Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM, et al. HPV vaccination impact on a cervical cancer screening program: Methods of the FASTER-Tlalpan Study in Mexico. Salud Publica Mex. 2016;58:211-9.

  34. Gravitt PE. HPV seroprevalence in the United States: Behavior, biology, and prevention. J Infect Dis. 2016;213:171-2.

  35. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711-23.

  36. León-Maldonado L, Allen-Leigh B, Lazcano-Ponce E. Counseling for HPV detection when used to screen for cervical cancer: A qualitative study on the needs of women from Michoacan, Mexico. Salud Publica Mex. 2014;56:519-27.

  37. León-Maldonado L, Wentzell E, Brown B, Allen-Leigh B, Torres- Ibarra L, Salmerón J, et al. Perceptions and experiences of human papillomavirus (HPV) infection and testing among low-income mexican women. PLoS One. 2016;11:e0153367.




2020     |     www.medigraphic.com